The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vi…

Refractory Solid TumorsRelapsed Solid TumorsRelapsed Neuroblastoma+3 more

~Estimated

~$10 – $7,500

Theodore LaetschNCT06721689

Phase 1

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back…

Recurrent Solid TumorRecurrent Ewing SarcomaRecurrent Hepatoblastoma+19 more

~Estimated

~$10 – $6,250

St. Jude Children's Research Hospital

NCT04901702